Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia
Cureus · 21.08.2026
DOI: 10.7759/cureus.114933 ↗Kurz gefasst
Editorial in der Zeitschrift Cureus, erschienen am 21.08.2026. Verfasst von Iván López-Ibor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, South Florida Integrative Medicine, Miami, USA. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
People with schizophrenia experience markedly reduced life expectancy, driven largely by cardiometabolic disease, and several of the most effective antipsychotics are also among those most likely to promote weight gain. Weight gain is among the adverse effects patients find least acceptable and one they frequently cite when they abandon treatment, which links metabolic harm directly to the non-adherence that precipitates relapse. Glucagon-like peptide-1 receptor agonists, now supported by randomized trials in schizophrenia-spectrum populations, reduce weight and metabolic burden without destabilizing psychiatric symptoms. In this editorial, we argue that their most consequential effect in serious mental illness may not be the weight they remove but the treatment they help patients keep taking: by neutralizing the adverse effect patients most resent, these agents may protect antipsychotic adherence itself. We call for trials that adopt adherence and discontinuation as endpoints and for psychiatry to reclaim ownership of cardiometabolic prescribing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, South Florida Integrative Medicine, Miami, USA.
- Department of Psychiatry, López Ibor Clinic, Madrid, ESP.
- Department of Psychology, Dr. Esquerdo Sanatorium, Madrid, ESP.
- Department of Psychiatry, Dr. Leon's Clinic, Madrid, ESP.
- Department of Psychiatry, Herbert Wertheim College of Medicine, Florida International University, Miami, USA.
- Department of Psychiatry, Texas A&M University - Central Texas, Killeen, USA.
Zitieren
APA
López-Ibor, I., Humphery, H., & Tafet, G. (2026). Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia. Cureus. https://doi.org/10.7759/cureus.114933
Vancouver
López-Ibor I, Humphery H, Tafet G. Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia. Cureus. 2026. doi:10.7759/cureus.114933
BibTeX
@article{LpezIbor2026,
author = {López-Ibor, Iván and Humphery, Hugh and Tafet, Gustavo},
title = {Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.114933}
}
EUVIMED